Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine for nocturnal hypokinesia in Parkinson's disease
NL-OMON35536Phase 4Recruiting
- Sponsor
- Kempenhaeghe
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by Kempenhaeghe. Primary endpoint: Position changes over the night. Started May 2012; status: recruiting.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON35536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35536.